FRM
SLDB icon

Fox Run Management’s Solid Biosciences SLDB Stock Holding History

Fox Run Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,228
Closed -$177K – 1272
2026
Q1 		$177K Buy
27,228
+2,223
+9% +$14.3K 0.03% 781
2025
Q4 		$141K Buy
25,005
+6,491
+35% +$35.2K 0.02% 840
2025
Q3 		$114K Buy
+18,514
New +$108K 0.02% 855
2025
Q2 		– Sell
-38,226
Closed -$141K – 1198
2025
Q1 		$141K Buy
+38,226
New +$164K 0.02% 839
2024
Q4 		– Sell
-15,453
Closed -$108K – 1150
2024
Q3 		$108K Buy
+15,453
New +$125K 0.02% 733
2021
Q1 		– Sell
-751
Closed -$85K – 304
2020
Q4 		$85K Buy
+751
New +$47.5K 0.17% 179

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's SLDB Position: Q2 2026 in Review

Fox Run Management sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 27,228 shares — an estimated $177K sold.

Fox Run Management first reported a position in SLDB in Q4 2020 and held it in 6 quarters. The position peaked at $177K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Fox Run Management reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 27,228 Solid Biosciences shares in Q2 2026, an estimated $177K.
  • Fox Run Management first reported a position in Solid Biosciences in Q4 2020 and held it in 6 quarters.
  • Fox Run Management's Solid Biosciences position peaked at $177K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.